Skip to main content

Table 2 Description of corticosteroid therapy among 183 critically ill patients with COVID-19

From: Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study

  Total, n = 183
Dexamethasonea 4 (2%)
Hydrocortisonea 11 (6%)
Methylprednisolonea 175 (96%)
Prednisonea 3 (2%)
Duration of corticosteroid treatment, day 9 (5–14)
Hydrocortisone equivalents per ICU day, mg/day 200 (100–320.9)
Duration between hospital admission and corticosteroid initiation, day 1 (0–5)
Duration between ICU admission and corticosteroid initiation, day 0 (0–2)
Duration between onset of ventilation and corticosteroid initiation, day 0 (0–4)
PaO2/FiO2 when corticosteroid initiation, mmHg 119 (82, 200)
SOFA score when corticosteroid initiation 4 (3, 6)
  1. Q quartile, SOFA Sequential Organ Failure Assessment
  2. aPercentages of dexamethasone, hydrocortisone, methylprednisolone and prednisone add to more than 100% because some patients received one or more formulation of corticosteroids. Data presented as n (%) or median (Q1–Q3)